We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SAR Sareum Holdings Plc

0.75 (4.55%)
Last Updated: 09:44:22
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Sareum Holdings Plc LSE:SAR London Ordinary Share GB00BMC3RJ87 ORD GBP 0.0125
  Price Change % Change Share Price Shares Traded Last Trade
  0.75 4.55% 17.25 558,679 09:44:22
Bid Price Offer Price High Price Low Price Open Price
17.00 17.50 17.75 16.50 16.50
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations -3.19M -0.0469 -3.52 11.23M
Last Trade Time Trade Type Trade Size Trade Price Currency
09:46:42 O 14,000 17.475 GBX

Sareum (SAR) Latest News

Sareum (SAR) Discussions and Chat

Sareum Forums and Chat

Date Time Title Posts
17/4/202409:37Sareum 2015 16,123
05/8/202108:49No more rns until current project closed-
04/7/202120:52SAR 2013 , SHORT THE ARSE OUT OF IT THREAD326
08/1/202118:09SAR - Sareum Holdings drug discovery370

Add a New Thread

Sareum (SAR) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Sareum (SAR) Top Chat Posts

Top Posts
Posted at 17/4/2024 09:20 by Sareum Daily Update
Sareum Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SAR. The last closing price for Sareum was 16.50p.
Sareum currently has 68,069,416 shares in issue. The market capitalisation of Sareum is £11,231,454.
Sareum has a price to earnings ratio (PE ratio) of -3.52.
This morning SAR shares opened at 16.50p
Posted at 15/4/2024 11:50 by peaceandlove
Of course the silver grey lady (see below) top sliced in 2021 🤣😆 PMSL at all you happy clappers who top sliced in June 2021 when the share price was at 9p. At the time everyone was holding for 28p - the month of rerate. Now you've all top sliced. In June 2021, Trimme told you to top slice and he was bullied into submission. No shame from you nasty people!

This little spike in the share price is predictable, as are all the happy clappers starting to shout £5 would be nice or even £2.50 per share. Shows me and everyone what uneducated fools you all are! 😆

A big dump coming, mark this post. Now I will explain yet again why I feel this is a bad investment. But you happy clappers have to at least put up one shed of evidence that shows this company will succeed? No 'If's or What ifs' Actual evidence, that is factual!

The Clinical Trial is a phase 1 protocol. This assesses only the basic safety of the new molecule and has nothing to do with whether it will work or not. It can be compared with base camp for the climb to the summit of Everest.

The MHRA refused Sareum a Phase 1 CTA (Clinical Trial Authorisation) despite the fact that an external & experienced Consultancy (CRO) had developed the novel capsule technology for them. I suspect the MHRA may have felt that the novel formulation was not a sufficient innovation to expose fit and healthy volunteer-patients to the risks of the clinical trial. By going to the Australian Regulator Authority Sareum hopes to use their diminishing financial resources to show that their prototype drug is safe enough to administer to sick patients in the future (Phase 2a and then Phase 2b).

In addition, Sareum will have to go back to investors to raise more money. This is not good and could result in more dilution of your share holding. I leave it to your imagination as to the struggle Sareum will have if the Phase 1 outcome is unfavourable.

Horrid, you come across as extremely inexperienced and naive to say you've been making money on this stock. You wouldn't be holding a single share here if you were experienced, the fact you do and you're underwater tells everyone that you're not. PMSL at you the most, you're such a prat!

Posts: 1,561
Price: 16.00
No Opinion

RE: Some taking profits on their 10p buysToday 11:11

Like you Mitty I got in in 2011 after the excitement of the mice trials .. sold 1/3 in July 2021 .. then topped up 2 weeks ago at 10p so hold more now than before but at a much lower average. A share price above £1 now would represent a sound investment anything above £2.50 would be brilliant anything above £5 would be stunning

🙄 You couldn't make it up. Market cap of £16million. The MCAP has gone up £6million in 2 weeks and the happy clappers are now talking a MCAP £492,895,545 from £16million. LMFAO at these muppets!
Posted at 07/4/2024 21:24 by peaceandlove
Wolf, the rampers are on a different planet to me. Sareum's current market value is correct, £8million based on the following.

1) No revenue.
2) Dilution with more on the cards.
3) As you say 737 was turned down by GSK.
4) None of Sareum's products are proven.
5) Phase 1 of the clinical trial is safety only.
6) The MHRA turned Sareum down for a clinical trial in the UK. This is an enormous red flag for me.
7) Board are still taking large salaries as 'working capital'.
8) It almost 20 years since Sareum were listed on AIM. 20 years and the share price 92% down.
9) No license deals even though Sareum's business model is to license pre clinical or early on in the clinical trial.

To be frank, Sareum have had 20 years and produced f all. What does that tell you?????? Oh yeah this is the year of rerate, the year of license deals, the year of 1801, the year of 737, the year of revenue. Come on Sar.... 😆🤣
Posted at 03/4/2024 08:53 by peaceandlove
Good morning,

At present the market doesn't think Sareum will ever be able to license their products. If something is highly likely to happen then this would already be built into the share price. The 10p share price (new money) currently suggests to me the market believes Sareum license deals are very unlikely to happen. Hence why the rampers believe if it does happen there will be a violent rerate. Rampers are betting against the market knowing better, which doesn't bode well.

Most of the rampers do not know what they're talking about and offer nothing in regard to evidence of their claims that this is the best thing since sliced bread.

The SOG's and Horrid's of this world are dreamers. Most probably wanting to retire because of mundane jobs. Most HNWIs wouldn't invest in a company like Sareum, so when Horrid is talking about beers in the sunshine or going to F1 events he is clearly dreaming like the rest of the rampers hoping that one day his so called golden tickets come in.
Posted at 02/4/2024 21:24 by peaceandlove
To be fair to Num4, it is a decent post. It's certainly fairer than the dross SOG and Laz put up.

Unfortunately, for me though, it's too optimistic. Even with safety data, 1801 hasn't enticed any pharmaceutical companies. Why is that? Sareum have always want to license pre clinical or early clinical trial. In addition, the MHRA had their reasons for not authorising the clinical trial in the UK. That in itself is a massive red flag.

For me Sareum is now taking advantage of shareholders hoping that this company will change their lives - total fantasy. It's up to them, but Sareum now know they can go to them for money. This could potentially drag on for years. I reckon the share price will continue to be diluted, coupled with no revenue, losses that will have increase and more importantly than anything else I do not think their products will be licensed. The share price will continue to fall.
Posted at 01/4/2024 09:42 by peaceandlove
Posts: 1,035
Price: 10.75
No Opinion

RE: Lessons for Bioentrepreneurs and InvestorsToday 09:25

If SAR data from p1 is good you can see from the reports data just how undervalued this share is at the current time.

Omg 😱 😆 Another deluded poster 🙄. The happy clappers are relentless.

The share price is overvalued IMO. Do you know what's going on here? Massive dilution, no revenue stream, million of pounds of losses, Safety data is one thing, but does it work?

Nope, sorry the share price is currently overvalued. Wait until you receive news of revenue streams. Could be waiting a longtime 😆🤣 share price will be below 5p sooner rather than later.
Posted at 29/3/2024 07:33 by peaceandlove
This is what annoys me from idiots ramping this stock 👇


Posted in: SAR
Posts: 2,504
Price: 10.75
No Opinion

Back to where we were 3 years ago but....Today 07:11

The share price is back to where we were 3 years ago but the science is further forward. Some of us have made good gains on Sareum from these levels. For me it was a near x25 in my ISA and SIPP. It’s about timing. If you still believe in the science then it is highly probable that this will multiply many times from the current and quite appalling 10p level. If the data for SRA737 and SDC1801/1802 turns out to be as good as some of us think then there is still going to be good money to be made here again. It’s whether investors now have faith in TM, share price and JR to deliver. That is an enormous conundrum.....

Good luck, Brighty.

A total lie. The share price was at 95p new money 3 years ago as at close of business yesterday.

These idiots think we're all stupid. Well you can ramp away and I will continue to call you fools out!
Posted at 29/3/2024 07:10 by peaceandlove
Good morning! Below is a post on LSE from Meg was Norma on here, before my time, but believes Wolf and I are the same person LOL. She sounds a lot like SOG LOL perhaps they are the same person? 🤔 She is also calling us 'It' how rude. 🤣

Posts: 15
Price: 10.75
No Opinion

RE: Valuation…28 Mar 2024 21:25

Some things are open to interpretation. I feel, having used it and then converted $ to E, that we’re currently worth somewhere between £86m and £117m. That involves me removing obscure outliers.

LOL, she is valuing Sar at these ridiculous values when it's current market cap is less than £8million 🤦🏻 Btw SOG Sareum hasn't gone bust yet because you and the happy clappers keep on investing because you're SO blinded by the science and think a license deal will happen. Not on your Nelly sunshine. I'll tell you why again.

The MHRA refused Sareum a Phase 1 CTA (Clinical Trial Authorisation) despite the fact that an external & experienced Consultancy (CRO) had developed the novel capsule technology for them.

The MHRA felt that the novel formulation was not a sufficient innovation to expose fit and healthy volunteer-patients to the risks of the trial. By going to the Australian Regulator Authority, Sareum will to use their diminishing financial resources to show that their prototype drug is safe enough to administer to sick patients in the future (Phase 2a and then Phase 2b).

As someone else, it's the last throw of the dice.

The Clinical Trial at present, phase 1 assesses only the basic safety of the molecule and has nothing to do with whether it will work or not. It can be compared with base camp for the climb to the summit of Everest. Therefore, even with good safety data it means nothing really. Why are LSE continuing to delude themselves with you SOG has being Chief Ramper. PLEASE STOP!

In addition to all of this, Sareum will have to further raise funds which means further dilution. More, more money will need to be raised and it'll be shareholders paying for it!

So Meg (Norma) and SOG as I said stop ramping and trying to con more people to invest more into a company that clearly has a mountain to climb. The share price is down nearly 85% since January this year, the market has spoken, you both and the other happy clappers are saying disgusting things to encourage innocent people to invest in a company that is a busted flush!

SOG, you should know better, grow up FFS.
Posted at 16/3/2024 08:15 by peaceandlove
Good morning the real Wolf, SOG is an unique character. He believes in the science and nothing and I mean nothing will ever change his mind. 1801 maybe worth $1billion plus (I personally don't think so), but as I keep saying the money has run out. Any other death spiral funding would finish the share price off once and for all. It's like the LSE board are ignoring the fact the company has no money and 1801 will come to the rescue. If large pharmaceutical were interested, and Sareum were on their radar, as others speculate they wouldn't have commenced with RF finance in the first place.

The first two paragraphs are what Sar board hoped would've happened.

A conventional convertible bond or preferred stock can be converted to a fixed number of shares. Death spiral debt, however, converts into a fixed value paid in shares.

As a stock's price increases substantially, investors in conventional convertible shares are likely to seize the opportunity to convert their bonds into fast-growing stocks.

The next paragraphs are the reality of the current situation.

However, a stock price decline motivates the owner of fixed value convertible bonds or shares. They can get more shares of stock when they make the conversion. This process by definition increases the number of shares in the market, and that forces prices even lower.

The death spiral effect occurs as more and more fixed-value convertible instrument owners convert their holdings into common stock as their value drops lower and lower.

Theoretically, the death spiral effect can continue until the stock is at or near zero value.

Lastly this is what I believe will happen.

Sareum desperately needs cash. I suspect Sareum probably had no other way to raise money to survive particularly with the cost of the clinical trials. Unfortunately, 1801 is not ready to license. Why? We don't know? I just can't see Sar's board dropping an RNS stating someone wants it for $100,000 let alone $400million as SOG believes.

Have a good weekend Wolf and don't bother engaging with the fool. Waste of your time. Cheers
Posted at 14/3/2024 19:20 by peaceandlove
You're are correct Wolf. The LTH's feel 1801 will be sold for hundreds of millions if not billions of dollars. You couldn't make up what they're saying. It's not going to happen.

Unfortunately, as you probably know 90% of drug trials fail. One of the biggest reasons this happens is the high cost of clinical trials. Clinical trials are necessary to prove the safety and efficacy of a new drug or treatment, but they can cost hundreds of millions of dollars. No one will buy 1801. Why would you? There're around 50,000 plus clinical trials a year and 90% fail. You've to have an unique product and Sar do not.

There is no more money. It's been exhausted. They've been around for 20 years and their share price is down -85%. That alone tells the story. It's over at Sareum. The smart people sold up a long time ago when the share price was at £4.50 - £5.00 a share. Greed takes over on Aim shares. I've been there. The greedy shareholders will lose everything, but I expect they'll go down fighting to the bitter end. Bulldog spirit! The end.
Posted at 12/3/2024 18:21 by criticalthinker1
4th Feb 2022 from Sareum BODS

Sareum Holdings PLC - Cambridge, England-based drug developer for cancer and autoimmune diseases - Calls extraordinary general meeting for February 28 to approve a 50-into-1 share consolidation. Sareum says its current large number of shares, at 3.40 billion, and low share price create a negative perception among investors. Reducing the number of shares by a factor of 50 will increase the share price and make the stock "more attractive to a broader range of investors", it says.

So they decided after apointing Peel Hunt on 29.10.21 that an EGM wad the way forward no doubt on advice from Peel Hunt who we pay!
So it is not disproportionate to ask for an EGM from the shareholders is it!?
And note if you draw the line on the share price from when Peel Hunt joined it is a direct descent and VERY questionable abilities provided what do they do?
We have bolstered our IPR and 737 back 'somewhere'. Still heard no one on lse pick up on my point re where trials take place because we got screwed last time. If they have screwed that then definitely corruption is apparent.
We could have raised before around 2.50
But silence on that
And plenty more we will look into but don't forget a poster on lse lauded a chap at the last meeting as the introducer.
Well what happens to their (at the time) 29000000 shares at exercise price of 5p (at the time) executable by 31.5.26.
Like I say more to dovetail re MAERS and NOMAD responsibilities but will get appropriation of who is not doing their job. Which entails fines and possible dismemberment of providing services or acting as a director for x time
All best Steadydanny
Sareum share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock